WallStreetZenWallStreetZen

NASDAQ: TBPH
Theravance Biopharma Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Theravance Biopharma revenue was $107.46M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $45.9M, up 129.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TBPH annual revenue was $107.5M, with 66.9% growth year-over-year.

TBPH past revenue growth

How has TBPH's revenue growth performed historically?

Company
66.92%
Industry
466.16%
Market
89.29%
TBPH's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TBPH's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TBPH's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TBPH revenue history

Current Revenue
$107.5M
Current Earnings
$105.9M
Current Profit Margin
98.5%

Be the first to know when TBPH announces revenue.

TBPH Revenue History By Year

TBPH Yearly RevenueTBPH RevenueTBPH ChangeTBPH Revenue Growth
2025-12-31$107.46M$43.08M+66.92%
2024-12-31$64.38M$6.96M+12.12%
2023-12-31$57.42M$6.08M+11.84%
2022-12-31$51.35M-$3.97M-7.17%
2021-12-31$55.31M-$16.55M-23.03%
2020-12-31$71.86M-$1.56M-2.12%
2019-12-31$73.41M$13.04M+21.61%
2018-12-31$60.37M$44.98M+292.37%
2017-12-31$15.39M-$33.26M-68.37%
2016-12-31$48.65M$6.52M+15.48%
2015-12-31$42.13M$30.44M+260.42%
2014-12-31$11.69M$11.46M+5,071.68%
2013-12-31$226.00k-$129.92M-99.83%
2012-12-31$130.15M$115.29M+776.16%
2011-12-31$14.85MN/AN/A

1 of 1

Theravance Biopharma Revenue FAQ

What was TBPH's revenue last quarter?

On Invalid Date, Theravance Biopharma (NASDAQ: TBPH) reported Q4 2025 revenue of $45.89 million up 144.7% year over year. In the same quarter last year, Theravance Biopharma's revenue was $18.75 million.

What was Theravance Biopharma's revenue in 2025?

Theravance Biopharma's annual revenue for the twelve months ending Dec 31, 2025 was $107.46 million, a 66.92% increase year over year.

How much does Theravance Biopharma make in a day?

Based on Theravance Biopharma annual revenue for the past five years, TBPH makes an average of $184,069.04 per day.

What was Theravance Biopharma's annual revenue growth in the past year?

As of Q2 2026, Theravance Biopharma's revenue has grown 66.92% year over year. This is 399.24 percentage points lower than the US Biotechnology industry revenue growth rate of 466.16%. Theravance Biopharma's revenue in the past year totaled $107.46 million.

How much does Theravance Biopharma make in a year?

Theravance Biopharma's revenue by year for the past five years is:
  • Theravance Biopharma's revenue for the twelve months ending Dec 31, 2025 was $107.46 million, a 66.92% increase year over year.
  • Theravance Biopharma's annual revenue for Dec 31, 2024 was $64.38 million, a 12.12% increase from 2023.
  • Theravance Biopharma's annual revenue for 2023 was $57.42 million, a 11.84% increase from 2022.
  • Theravance Biopharma's annual revenue for 2022 was $51.35 million, a 7.17% decrease from 2021.
  • Theravance Biopharma's annual revenue for 2021 was $55.31 million, a 23.03% decrease from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.